Latest moves, page 3
-
Alnylam: our view and what our model says about 2030
Our analysis of Alnylam after Q3: slower Amvuttra demand, the 340B and payer pressure, the new buyback and what 50,000 simulations say about end-2030 value.
-
Vera Q3 2026: first Trutakna sales of $10.3M, about half inventory; a rival's FDA date nears
Vera reported first sales of $10.3 million, about half of it inventory, and filed for full approval; Vertex's rival drug has an FDA date of Nov 30.
-
Palantir: our view and what our model says about 2030
Our analysis of Palantir after Q3: slower contract signings, a thin contracted backlog, its high multiple and what 50,000 simulations say about end-2030 value.
-
Agios Q3 2026: record sales, R&D cuts, a 2028 non-GAAP profit goal; shares fall 10%
Agios sales rose 24% from Q2 and it set a 2028 non-GAAP profit goal and cut R&D jobs, but the shares fell about 10% as the sickle cell decision waits.
- WRBY Up 22.5% New
Warby Parker jumps 22% on a dark day for stocks, with AI glasses near
Warby Parker rose 22.5% as the S&P 500 fell 4.4%. Its numbers changed little; AI glasses pre-orders open Nov 12, after a 27% slide since August.
- VCYT Down 54.3% New
Veracyte falls 54% as its prostate test growth target is cut
Veracyte beat third-quarter forecasts, but its Decipher prostate test fell short again and it expects only mid-single-digit revenue growth in 2027.
-
Chip stocks sink 12%, Nasdaq 6% as AI worries erase the election rally
Weak Qualcomm and Arm results and worry about data-center rules hit chip stocks. The AI build-out stocks we track have kept falling since October.
-
Astera Labs: our view and what our model says about 2030
Our analysis of Astera Labs after its Q3 results: the Scorpio ramp, customer concentration, stock pay and what 50,000 simulations say about its end-2030 value.
- NRIX Down 38.2% New
Nurix falls 38% as Sanofi ends a partnered drug program
Nurix fell 38% after Sanofi ended the STAT6 drug program, removing about $455M of possible milestones. Nurix gave no reason.
-
Solar jumps 6%, gold miners 9% as Democrats win Congress; AI builders slide
Solar, gold miners and homebuilders rose on what a Democratic Congress might do, while data-center builders fell. The law itself has not changed.
- DOX Down 30.1% New
Amdocs falls 30% as T-Mobile fight darkens its 2027 outlook
Amdocs guided fiscal 2027 revenue down 14.3% to 17.9% and disclosed a contract fight with T-Mobile, with each side accusing the other of material breach.
- KD Up 30.1% UPDATED NOV 6New
Kyndryl jumps 30% as deal signings surge, though revenue fell
Kyndryl's revenue fell 1.9% and its forecast only held, but deal signings jumped to $4.1 billion and the stock rose sharply after its February collapse.
-
Astera Labs Q3 2026: big beat, a 53% buyer, shares 4% lower
Astera Labs beat forecasts and guided well above them, but one direct buyer reached 53% of sales and the shares closed 4.4% lower on Nov 4.
- FISV Up 12.5% New
Fiserv jumps 12% despite a $6.5B writedown as it doubles its savings goal
Fiserv took a $6.45 billion writedown and reported flat organic revenue, but doubled its savings goal, kept its forecast and planned $500 million of buybacks.
-
Madrigal: our view and what our model says about 2030
Our analysis of Madrigal after its first profitable quarter: patient growth, rebates, the cirrhosis trial and what 50,000 simulations say about its end-2030 value.
-
Shorter belts, smaller plates: how GLP-1 drugs are reaching far beyond pharma
One US adult in eight says they take a GLP-1 drug. The change shows up in belts, grocery bills and state budgets, and less neatly in the stocks investors first sold.
-
Madrigal Q3 2026: first profit and a sales beat, yet shares end 8% lower
Madrigal shares reversed an early 11% gain and closed 8.1% lower, even though sales beat forecasts and it reported its first quarterly profit.
- IT Down 13.2% New
Gartner falls 13% as growth outside the federal government slows
Gartner beat profit estimates and raised its outlook, but contract growth outside the U.S. federal government slowed, and a 4% pace by year-end now looks unlikely.
- DT Down 14.7% New
Dynatrace falls 15% as its AI deal and more shares cut its profit outlook
Dynatrace beat estimates and added a $1 billion buyback, but it cut its full-year profit-per-share forecast to include its $915 million Arize purchase.
-
War and Peace: what 50 years of conflicts say about oil stocks
Oil stocks fell and airlines rose as Brent dropped 7.6% on Nov 2; after most past Mideast wars, energy stocks trailed the S&P 500 a year later.